Seeking Alpha

Momenta Pharmaceuticals (MNTA) gains 5.7% AH after announcing it has entered into a...

Momenta Pharmaceuticals (MNTA) gains 5.7% AH after announcing it has entered into a collaboration with Baxter (BAX) to develop a class of drugs called biosimilars. As part of the deal, Baxter will make a $33M up-front payment to Momenta related to the development of six drug compounds, and "may make additional payments over the next several years."
From other sites
Comments (1)
  • Morochito
    , contributor
    Comment (1) | Send Message
     
    I have owned MNTA for a couple of years now, and use it mostly to sell Call Options against it which have served me well. What do you do?
    28 Dec 2011, 10:02 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs